Turnabout is fair playfor bone densitometry firm Hologic. The Waltham, MA, company raisedthe stakes this month in its legal battle with Lunar, filing acountersuit that accuses its competitor of infringing on its patents.The suit seeks to have three Lunar
Turnabout is fair playfor bone densitometry firm Hologic. The Waltham, MA, company raisedthe stakes this month in its legal battle with Lunar, filing acountersuit that accuses its competitor of infringing on its patents.The suit seeks to have three Lunar patents invalidated.
Lunar, of Madison, WI, fired the opening salvo last month whenit filed a federal lawsuit in U.S. District Court for the EasternDistrict of Wisconsin (SCAN 9/14/94). Lunar said that Hologic'smorphometry process is covered by three Lunar patents and askedthe court to overturn several Hologic patents.
Hologic's countersuit, filed in U.S. District Court for theDistrict of Massachusetts, charges that Lunar is infringing ontwo of Hologic's patents and asks for injunctive relief and damages.The complaint also seeks a declaration that Hologic does not infringeon three Lunar patents, which should be invalidated, accordingto the company. Finally, Hologic is asking for injunctive reliefand damages in connection with what the company said was "Lunar'sdissemination of false and misleading information which misrepresentsand disparages the quality of Hologic's bone densitometry products."
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.